This Article Full Text Full Text (PDF) All Versions of this Article: 34/12/2922    most recent 01.STR.0000099124.84425.BBv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Di Napoli, M. Articles by Papa, F. Search for Related Content PubMed PubMed Citation Articles by Di Napoli, M. Articles by Papa, F. Related Collections Acute Cerebral Infarction Primary and Secondary Stroke Prevention Risk Factors for Stroke Other Stroke Treatment - Medical

(Stroke. 2003;34:2922.)
© 2003 American Heart Association, Inc.

Original Contributions

Angiotensin-Converting Enzyme Inhibitor Use Is Associated With Reduced Plasma Concentration of C-Reactive Protein in Patients With First-Ever Ischemic Stroke

From the Neurological Section, SMDN–Center for Cardiovascular Medicine and Cerebrovascular Disease Prevention, Sulmona (L’Aquila), Italy.

Correspondence to Dr Mario Di Napoli, MD, Neurological Section, SMDN–Center for Cardiovascular Medicine and Cerebrovascular Disease Prevention, Via Trento 41, 67039 Sulmona (AQ), Italy. E-mail mariodinapoli{at}katamail.com

Background and Purpose— High levels of C-reactive protein (CRP) are associated with an increased risk of future cardiovascular events in ischemic stroke. It has been hypothesized that the benefit of angiotensin-converting enzyme (ACE) inhibitors in patients at high vascular risk may also result from their anti-inflammatory action. Data evaluating this hypothesis are limited in ischemic stroke.

Methods— We conducted a prospective observational study in 507 patients with first-ever ischemic stroke to analyze the effect of ACE inhibitor treatment at the time of stroke onset on CRP levels within the first 24 hours and the relationship to outcome. Risk estimates were calculated according to Cox regression analysis controlled for blood pressure (BP) levels, clinical and neuroradiological confounding variables, and log-normalized CRP levels at entry.

Results— ACE inhibitor treatment was associated with lower (2.6-fold; P<0.0001) median CRP levels and with a reduced 2-year cardiovascular risk (hazard ratio, 0.39; 95% CI, 0.29 to 0.53; P<0.0001) compared with a different BP-lowering regimen. The relationship between ACE inhibitor status and log-normalized CRP levels remained significant (P<0.0001) after we controlled for important confounding variables and concomitant treatments. The reduced risk was also evident in multivariable analysis when ACE inhibitor treatment was controlled for BP, associated risk factors, neuroradiological findings, and concomitant treatments (hazard ratio, 0.43; 95% CI, 0.30 to 0.62; P<0.0001). This risk reduction was greatly attenuated and not more significant when log-normalized CRP levels were included (hazard ratio, 0.67; 95% CI, 0.43 to 1.04; P=0.0721) in the model.

Conclusions— Concomitant treatment with ACE inhibitor at the time of an acute stroke is associated with lower inflammatory response and better long-term outcomes, apparently apart from the effects on BP.

Key Words: angiotensin-converting enzyme inhibitors • C-reactive protein • inflammation • stroke, ischemic

This article has been cited by other articles:

				B. M. Egan, S. D. Nesbitt, and S. Julius Review: Prehypertension: should we be treating with pharmacologic therapy? Therapeutic Advances in Cardiovascular Disease, August 1, 2008; 2(4): 305 - 314. [Abstract] [PDF]

				M. E. Suliman, A. R. Qureshi, O. Heimburger, B. Lindholm, and P. Stenvinkel Soluble adhesion molecules in end-stage renal disease: a predictor of outcome Nephrol. Dial. Transplant., June 1, 2006; 21(6): 1603 - 1610. [Abstract] [Full Text] [PDF]

				S. Kumar, S. Savitz, G. Schlaug, L. Caplan, and M. Selim Antiplatelets, ACE inhibitors, and statins combination reduces stroke severity and tissue at risk Neurology, April 25, 2006; 66(8): 1153 - 1158. [Abstract] [Full Text] [PDF]

				A. Mahmud and J. Feely Arterial Stiffness Is Related to Systemic Inflammation in Essential Hypertension Hypertension, November 1, 2005; 46(5): 1118 - 1122. [Abstract] [Full Text] [PDF]

				J. Amar, J.-B. Ruidavets, J.-C. Peyrieux, J.-M. Mallion, J. Ferrieres, M. E. Safar, and B. Chamontin C-Reactive Protein Elevation Predicts Pulse Pressure Reduction in Hypertensive Subjects Hypertension, July 1, 2005; 46(1): 151 - 155. [Abstract] [Full Text] [PDF]

				M. Di Napoli, M. Schwaninger, R. Cappelli, E. Ceccarelli, G. Di Gianfilippo, C. Donati, H. C.A. Emsley, S. Forconi, S. J. Hopkins, L. Masotti, et al. Evaluation of C-Reactive Protein Measurement for Assessing the Risk and Prognosis in Ischemic Stroke: A Statement for Health Care Professionals From the CRP Pooling Project Members Stroke, June 1, 2005; 36(6): 1316 - 1329. [Abstract] [Full Text] [PDF]

				A. H. Berg and P. E. Scherer Adipose Tissue, Inflammation, and Cardiovascular Disease Circ. Res., May 13, 2005; 96(9): 939 - 949. [Abstract] [Full Text] [PDF]